Targeting of SOX2-related upstream/downstream signaling pathways has become a more plausible approach, and pharmacological blockade of either the FBXW2-MSX2 axis with pevonedistat [12], the EGFR-STAT3 pathway with the cationic triphenylmethane pharmacophore gentian violet [13], or EGFR/SRC/AKT signaling with the EGFR inhibitors gefitinib and erlotinib and the Src inhibitor dasatinib [14], have been proposed as strategies to target human cancers with SOX2 overexpression. This evidence concerns the gene SRC and cancer.